|
2025
|
Invention
|
Pharmaceutical composition for use in prevention and/or treatment of disease that develops or pro... |
|
|
Invention
|
Multi-specific antigen-binding molecule having alternative function to function of blood coagulat... |
|
|
Invention
|
Polypeptide modification method for purifying polypeptide multimers.
The present invention provi... |
|
|
Invention
|
Cell culture method using amino acid-enriched medium.
Methods of culturing cells capable of prod... |
|
|
Invention
|
Antibody variant and isoform with lowered biological activity.
As antibody variants and isoforms... |
|
|
Invention
|
Antibody molecules.
The present invention provides pharmaceutical compositions comprising second... |
|
|
Invention
|
Anti-dengue virus antibodies, polypeptides containing variant fc regions, and methods of use.
Th... |
|
|
Invention
|
Prediction method, prediction device, prediction program, and prediction model. This prediction m... |
|
|
Invention
|
Solid dispersion and composition containing same. This solid dispersion comprises: a component (1... |
|
|
Invention
|
Cross-species anti-latent tgf-beta 1 antibodies and methods of use.
The objective of the inventi... |
|
|
Invention
|
Method for synthesizing peptides in cell-free translation system.
An objective of the present in... |
|
|
Invention
|
Anti-hla-dq2.5 antibody.
The antibodies of the present invention have specific binding activity ... |
|
|
Invention
|
Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coa... |
|
|
Invention
|
Method for quantifying mispaired light chain exchanger of bispecific antibody. According to the p... |
|
|
Invention
|
Antibody substituting for function of blood coagulation factor viii.
The present inventors produ... |
|
|
Invention
|
Genetically modified non-human animal. Provided are: a genetically modified non-human animal that... |
|
|
Invention
|
High concentration antibody-containing liquid formulation.
The problem to be solved is to provid... |
|
|
Invention
|
Treatment and prevention of muscular dystrophy and its related diseases or disorders with satrali... |
|
|
Invention
|
O-substituted serine derivative production method.
It was discovered that a cyclic sulfamidate c... |
|
|
Invention
|
Methods for producing cyclic compounds comprising n-substituted amino acid residues.
The present... |
|
|
Invention
|
Method for calculating relative ratio (sij) of reaction rate constant between trinucleotides, and... |
|
|
Invention
|
Anti-cd137 antigen-binding molecule and utilization thereof.
An objective of the present disclos... |
|
|
Invention
|
Peptide, surfactant having sugar fatty acid ester structure, and pharmaceutical composition conta... |
|
|
Invention
|
Composition for treating il-6-related diseases.
The present invention provides a pharmaceutical ... |
|
|
Invention
|
Method for predicting therapeutic effect of combination therapy of il-6 inhibitor and chemotherap... |
|
|
Invention
|
Methods of treating myasthenia gravis. The present disclosure provides methods for treating patie... |
|
|
Invention
|
Method for producing peptide compound having ring structure. The present invention provides a nov... |
|
|
Invention
|
Anti-dll3 antibody.
An antibody which binds to DLL3 protein, composition containing the antibody... |
|
|
Invention
|
Use of myt1 inhibitor. The present invention provides a pharmaceutical composition comprising, as... |
|
|
Invention
|
Method for producing sulfonamide compound using sulfonyl triazolium. The present invention provid... |
|
|
Invention
|
Method for producing sulfonamide compound using 4-aminopyridine derivative. The present invention... |
|
|
Invention
|
Information processing system, information processing method, and information processing program.... |
|
|
Invention
|
Cd3-targeting antigen-binding molecule with improved stability. The present disclosure provides a... |
|
|
Invention
|
Cell culture medium.
Provided are a method, an agent, or the like for improving the stability of... |
|
|
Invention
|
Method for measuring cellular uptake of molecules.
The present invention provides a method for m... |
|
|
Invention
|
Antigen-binding molecules that bind pdgf-b and pdgf-d, and methods of use. The present invention ... |
|
2024
|
Invention
|
Dosage and administration regimen for the treatment or prevention of guillan-barre syndrome by th... |
|
|
Invention
|
Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by th... |
|
|
Invention
|
Cytotoxicity-inducing therapeutic agent.
Novel multispecific antigen-binding molecules maintaini... |
|
|
Invention
|
Amorphous form of tetracyclic compound.
An amorphous form of 9-ethyl-6,6-dimethyl-8-(4-morpholin... |
|
|
Invention
|
Cell culture method and system. Provided is a culture method for maintaining the productivity of ... |
|
|
P/S
|
Pharmaceutical preparations. Providing education and training services in the medical
field. Pro... |
|
2023
|
Invention
|
Method for producing amino acid and peptide compound, using enzyme and additive.
One aspect of t... |
|
|
Invention
|
Method for producing salt of amino acid or salt of peptide compound or solvate of either one of s... |
|
|
Invention
|
Pharmaceutical composition for treating or preventing cystic disease.
The present invention prov... |
|
|
Invention
|
Peptide synthesis method for suppressing defect caused by diketopiperazine formation.
Synthesis ... |
|
|
Invention
|
Title of invention: pharmaceutical-preparation-containing syringe equipped with filter.
An objec... |
|
|
Invention
|
Pharmaceutical for treating or preventing cancer.
The present invention provides a drug for trea... |
|
|
Invention
|
Production method for peptide compound.
A method for producing a peptide compound by a solid pha... |
|
2022
|
Invention
|
Composition including peptide compound and surfactant.
The present invention relates to a compos... |
|
|
Invention
|
Pulmonary arterial hypertension patient selection method and biomarker.
The present invention re... |
|
2021
|
P/S
|
Pharmaceutical preparations. |
|
|
P/S
|
Pharmaceutical research and development services and providing information about medical and scie... |
|
|
P/S
|
Pharmaceutical preparations for human use, namely, pharmaceutical antibodies or its fragments or ... |
|
2020
|
P/S
|
Pharmaceuticals consisting of antibodies or its fragments or
its derivatives, cells or genes tha... |
|
2019
|
P/S
|
Pharmaceutical research and development services and
providing information about medical and sci... |
|
|
P/S
|
Pharmaceuticals consisting of antibodies or its fragments or
its derivatives; cells or genes tha... |
|
2017
|
P/S
|
Providing educational classes, seminars, workshops, symposiums and conferences and training servi... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of neuromyelitis optica spectrum disorder |
|
2015
|
P/S
|
Pharmaceutical preparations for the treatment of hemophilia A. |
|
|
P/S
|
[ Pharmaceutical oncology preparations ] Providing educational classes, seminars, workshops, symp... |
|
|
P/S
|
pharmaceutical preparations for the treatment of Hemophilia A |
|
2013
|
P/S
|
pharmaceutical preparation, namely, an anti-cancer drug |
|
2012
|
P/S
|
Injection devices for medical purposes. |
|
|
P/S
|
injection devices for medical purposes |
